HMGN3 Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population in which the HMGN3 gene has been disrupted in the NCI-H1975 human lung adenocarcinoma cell line. This polyclonal knockout product provides a heterogeneous pool of edited alleles, enabling functional investigation of HMGN3 loss-of-function without single-cell cloning. The knockout efficiently ablates HMGN3 protein expression, creating a powerful model to study its role in chromatin architecture and transcriptional regulation in a cancer-relevant background.
The host cell line NCI-H1975 is derived from a non-smoking female with lung adenocarcinoma and harbors both L858R and T790M mutations in the epidermal growth factor receptor (EGFR). These mutations render the cells dependent on EGFR signaling and confer resistance to first-generation tyrosine kinase inhibitors (TKIs), making NCI-H1975 a widely used model for acquired EGFR TKI resistance. The epithelial nature of these cells and their genetic background provide a clinically relevant context for exploring the interplay between chromatin dynamics and oncogenic signaling.
HMGN3 encodes a nucleosome-binding protein that reduces chromatin compaction by interacting directly with histones H3 and H4, thereby facilitating the access of transcription factors to their target sites. As a transcriptional coregulator, HMGN3 partners with nuclear receptors such as estrogen receptor alpha (ESR1) and thyroid hormone receptor beta (THRB), modulating the expression of downstream effectors including SLC2A2 (GLUT2), insulin (INS), and CCND1 (cyclin D1). HMGN3 activity is promoted by upstream signals from ESR1, THRB, and Wnt pathway component CTNNB1, and it acts in concert with chromatin remodelers like SMARCA4 (BRG1). Loss of HMGN3 disrupts this network, potentially impairing estrogen-responsive transcription, metabolic gene regulation, and cell cycle progression.
In NCI-H1975 cells, HMGN3 knockout offers a valuable tool to dissect how chromatin-level modulation influences EGFR-dependent oncogenic programs and drug sensitivity. Given that this cell line is a model of T790M-mediated TKI resistance, abrogating HMGN3-mediated chromatin relaxation may alter the transcriptional output of key proliferation and survival pathways, thereby impacting responses to EGFR inhibitors. Moreover, because HMGN3 is implicated in insulin secretion and metabolic regulation through its effects on INS and SLC2A2, this model also enables exploration of metabolic adaptations in lung adenocarcinoma, potentially linking chromatin architecture to metabolic syndrome?Crelevant pathways.
Typical research applications include mechanistic studies of EGFR TKI resistance, chromatin remodeling, and transcriptional regulation of oncogenic and metabolic gene networks. The polyclonal knockout population is suitable for a range of assays including western blotting and RT-qPCR to confirm target depletion, RNA-seq and ChIP-qPCR to assess global transcriptomic and epigenetic changes, and functional experiments such as cell proliferation, drug sensitivity, and migration assays. Immunofluorescence can be employed to visualize chromatin or signaling alterations. For further information or technical support, please contact Ascent Research.
